The National Pharmaceutical Pricing Authority (NPPA) on September 10, 2026has determined the retail price of the formulation “Each 5 ml contains: Ibuprofen IP 100 mg + Paracetamol IP 162.5 mg” for M/s Innova Captab Ltd. (Manufacturer) and M/s Torrent Pharmaceuticals Ltd. (Marketer) under Paragraph 5 of the Drugs (Prices Control) Order, 2013 (DPCO, 2013). The price computation is based on January 2026 market data.
The calculation considers various brands of the same formulation marketed by multiple companies, including Brufen P, Anaflam P, Flexon, Ibugesic Plus, IBUKIND Plus, Combiflam Paed and Imol, among others. The data includes market share, Moving Annual Turnover (MAT), Price to Retailer (PTR) and number of packs considered for determining the average price. The document records the worked-out retail price at ₹0.60 per ml, excluding GST, with the proposed retail price also fixed at ₹0.60 per ml, excluding GST, after applying the prescribed retailer margin.
Accordingly, the retail price for the specified formulation is proposed/determined at ₹0.60 per ml excluding GST, pursuant to the price-calculation mechanism under DPCO, 2013. The matter relates to drug price regulation and pharmaceutical manufacturers/marketers, and requires compliance with the retail price fixed by NPPA for the specified formulation.
[File No. 19(5329)/2026/DP/NPPA/Div.II]
